SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 191 filers reported holding SANGAMO THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $49,207 | +22.3% | 73,421 | -0.9% | 0.00% | – |
| Q4 2023 | $40,232 | -6.8% | 74,051 | +2.9% | 0.00% | – |
| Q3 2023 | $43,175 | -52.2% | 71,983 | +3.7% | 0.00% | -100.0% |
| Q2 2023 | $90,250 | -20.6% | 69,423 | +7.5% | 0.00% | 0.0% |
| Q1 2023 | $113,666 | -42.8% | 64,583 | +2.0% | 0.00% | 0.0% |
| Q4 2022 | $198,756 | -33.1% | 63,298 | +4.3% | 0.00% | -50.0% |
| Q3 2022 | $297,000 | +28.0% | 60,688 | +8.3% | 0.00% | 0.0% |
| Q2 2022 | $232,000 | -32.4% | 56,061 | -4.9% | 0.00% | 0.0% |
| Q1 2022 | $343,000 | -27.5% | 58,952 | -6.6% | 0.00% | 0.0% |
| Q4 2021 | $473,000 | -19.3% | 63,101 | -2.9% | 0.00% | -33.3% |
| Q3 2021 | $586,000 | -25.6% | 64,989 | -1.3% | 0.00% | 0.0% |
| Q2 2021 | $788,000 | -6.3% | 65,867 | -1.9% | 0.00% | 0.0% |
| Q1 2021 | $841,000 | -19.5% | 67,112 | +0.3% | 0.00% | -25.0% |
| Q4 2020 | $1,045,000 | +60.5% | 66,935 | -2.8% | 0.00% | +33.3% |
| Q3 2020 | $651,000 | +3.2% | 68,855 | -2.2% | 0.00% | 0.0% |
| Q2 2020 | $631,000 | +45.7% | 70,421 | +3.6% | 0.00% | +50.0% |
| Q1 2020 | $433,000 | -28.1% | 68,004 | -5.5% | 0.00% | 0.0% |
| Q4 2019 | $602,000 | -8.2% | 71,932 | -0.8% | 0.00% | -33.3% |
| Q3 2019 | $656,000 | -16.6% | 72,537 | -0.7% | 0.00% | 0.0% |
| Q2 2019 | $787,000 | +27.6% | 73,042 | +12.9% | 0.00% | +50.0% |
| Q1 2019 | $617,000 | -19.5% | 64,672 | -3.1% | 0.00% | -33.3% |
| Q4 2018 | $766,000 | -32.8% | 66,768 | -0.8% | 0.00% | -25.0% |
| Q3 2018 | $1,140,000 | +21.5% | 67,282 | +1.8% | 0.00% | +33.3% |
| Q2 2018 | $938,000 | -7.9% | 66,070 | +23.3% | 0.00% | -25.0% |
| Q1 2018 | $1,018,000 | +9.9% | 53,597 | -5.1% | 0.00% | +33.3% |
| Q4 2017 | $926,000 | +12.1% | 56,481 | +2.6% | 0.00% | 0.0% |
| Q3 2017 | $826,000 | +111.8% | 55,041 | +24.3% | 0.00% | +200.0% |
| Q2 2017 | $390,000 | +75.7% | 44,268 | +3.6% | 0.00% | 0.0% |
| Q1 2017 | $222,000 | +82.0% | 42,747 | +7.1% | 0.00% | – |
| Q4 2016 | $122,000 | -99.9% | 39,929 | -0.3% | 0.00% | -100.0% |
| Q3 2016 | $185,348,000 | -19.9% | 40,032 | +0.2% | 0.00% | 0.0% |
| Q2 2016 | $231,432,000 | -6.3% | 39,971 | -1.9% | 0.00% | 0.0% |
| Q1 2016 | $247,000,000 | -33.6% | 40,753 | 0.0% | 0.00% | -50.0% |
| Q4 2015 | $372,000,000 | +161639.1% | 40,753 | -0.2% | 0.00% | +100.0% |
| Q3 2015 | $230,000 | -99.9% | 40,824 | +0.1% | 0.00% | -50.0% |
| Q2 2015 | $452,206,000 | -32.5% | 40,776 | -4.6% | 0.00% | -33.3% |
| Q1 2015 | $670,038,000 | +3.1% | 42,732 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $649,954,000 | +35.7% | 42,732 | -3.8% | 0.00% | +50.0% |
| Q3 2014 | $479,091,000 | -29.4% | 44,422 | -0.1% | 0.00% | -33.3% |
| Q2 2014 | $678,828,000 | -11.6% | 44,455 | +4.7% | 0.00% | -25.0% |
| Q1 2014 | $767,894,000 | +33.3% | 42,472 | +2.4% | 0.00% | +33.3% |
| Q4 2013 | $576,102,000 | +47.7% | 41,476 | +11.4% | 0.00% | +50.0% |
| Q3 2013 | $390,067,000 | +33.5% | 37,219 | -0.5% | 0.00% | 0.0% |
| Q2 2013 | $292,172,000 | – | 37,410 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alexandria Capital, LLC | 968,505 | $12,135,000 | 1.23% |
| Golden State Equity Partners | 126,608 | $1,586,000 | 0.90% |
| McGuire Investment Group, LLC | 272,801 | $3,418,000 | 0.72% |
| Lombard Odier Asset Management (Switzerland) SA | 848,429 | $10,631,000 | 0.70% |
| Rhenman & Partners Asset Management AB | 765,000 | $9,585,000 | 0.67% |
| EMC Capital Management | 72,061 | $903,000 | 0.64% |
| WASATCH ADVISORS LP | 10,328,423 | $129,415,000 | 0.58% |
| Ceeto Capital Group, LLC | 74,000 | $927,000 | 0.45% |
| Fort Sheridan Advisors LLC | 75,945 | $952,000 | 0.38% |
| Vanguard Capital Wealth Advisors | 34,580 | $388,679,000 | 0.33% |